Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Activated Brown Fat Controls Obesity and Metabolic Disorders

By BiotechDaily International staff writers
Posted on 08 May 2013
Image: First author Dr. Aaron Cypess is an assistant professor of medicine at Harvard Medical School (Photo courtesy of Joslin Diabetes Center, Beth Deaconess Medical Center, Harvard University Medical School).
Image: First author Dr. Aaron Cypess is an assistant professor of medicine at Harvard Medical School (Photo courtesy of Joslin Diabetes Center, Beth Deaconess Medical Center, Harvard University Medical School).
Researchers speculate that the development of new drugs to activate human brown adipose tissue (BAT) could lead to safe treatments for obesity and metabolic disorders.

White adipose tissue (WAT) stores excess calories, while BAT consumes molecular fuel for thermogenesis (heat generation) using the tissue-specific enzyme UCP1(uncoupling protein 1).

Investigators at Harvard Medical School (Boston, MA, USA) delved into the genetic expression and protein activities found in BAT to determine its possible future role in the treatment of obesity. To this end, they isolated neck fat from adult human volunteers and compared its gene expression, differentiation capacity, basal oxygen consumption, and oxygen consumption rate (OCR), to different mouse adipose depots.

Among findings reported in the April 21, 2013, online edition of the journal Nature Medicine was that the OCR of the human BAT cells from the deep location in the neck next to the longus colli was nearly 50% of the rate found for mouse BAT cells. In contrast, the OCR of human WAT was only one-hundredth of the OCR found in the most active human BAT from the longus colli depot.

The investigators established a protocol for growth in culture of new functional BAT cells (adipocytes) by differentiating precursor cells (preadipocytes) derived from both superficial and deep human neck fat tissue. When stimulated, these cells expressed the same genes as naturally occurring brown fat cells. The use of brown fat cells produced in vitro will encourage development of drugs and other treatments that increase BAT activity for the correction of obesity and other metabolic disorders.

“BAT is most abundant in the deep locations of the neck, close to the sympathetic chain and the carotid arteries, where it likely helps to warm blood and raise body temperature,” said first author Dr. Aaron M. Cypess, assistant professor of medicine at Harvard Medical School. “Now that we know where brown fat is, we can easily collect more cells for further study.”

“Our research has significant practical applications. If we stimulate the growth of brown fat in people, it may burn their white fat and help them lose weight, which lessens insulin resistance and improves diabetes,” said Dr. Cypess.

Related Links:

Harvard Medical School



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.